Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022

Tebentafusp Granted Rare EU Accelerated Assessment

 
• By Andrew McConaghie
EMA
Rapid assessment US and EU reviews could see tebentafusp become the TCR receptor therapy approved in early 2022

More from Business

More from Scrip